论文部分内容阅读
目的:研究辛伐他汀联合环磷腺苷在应用于冠心病慢性心力衰竭治疗的治疗效果。方法:在该院2012年3月至2013年3月期间,共收录治疗的84例冠心病慢性心力衰竭的患者,在应用联合药物治疗中观察记录,采用随机分配辛伐他丁应用环磷腺苷的不同比例来进行观察。结果:联合用药组只在治疗中的效果为97.61%,要明显高于辛伐他汀组73.80%经计数分析,P<0.05;和治疗前对比,辛伐他汀治疗组在经过治疗后的比较,联合组的治疗结果中,左心室血分数LVEF为(33.53±3.25)%、(43.42±3.21)%、(55.23±3.51)%;二尖瓣的不同时期舒张值E/A为(0.63±0.12)、(0.69±0.14)、(1.01±0.22),血流速度显著增加。脑钠肽方面的数据BNP则为(536.84±22.13)ng/ml、(117.21±11.56)ng/ml、(78.53±10.93)ng/ml;C反应蛋白CRP的数据为(24.01±2.31)mg/L、(17.02±1.08)mg/L、(8.29±0.82)mg/L,数据水平有明显降低,所以P<0.05,具有统计学意义。结论:在治疗冠心病慢性心衰患者的心功能衰竭疾病的过程中,能够很好的改善患者的心功能,具有很好的医疗效果。
Objective: To study the therapeutic effect of simvastatin combined with cyclic adenosine monophosphate in the treatment of chronic heart failure with coronary heart disease. Methods: During the period from March 2012 to March 2013, a total of 84 patients with CHD were enrolled in the study. The patients were treated with combination therapy and were randomly assigned to simvastatin. Cyclophosphamide Different proportions of glycosides were observed. Results: The effect of treatment group was 97.61%, which was significantly higher than that of simvastatin group (73.80%, P <0.05). Compared with that before treatment, after simvastatin treatment group was treated, In the combined treatment group, the left ventricular blood fraction LVEF was (33.53 ± 3.25)%, (43.42 ± 3.21)%, (55.23 ± 3.51)%, and the diastolic E / A was 0.63 ± 0.12 ), (0.69 ± 0.14), (1.01 ± 0.22), blood flow velocity increased significantly. (536.84 ± 22.13) ng / ml, (117.21 ± 11.56) ng / ml, (78.53 ± 10.93) ng / ml) for BNP and 24.01 ± 2.31 mg / L, (17.02 ± 1.08) mg / L and (8.29 ± 0.82) mg / L, respectively. There was a significant difference between the two groups (P <0.05). Conclusion: The treatment of heart failure patients with heart failure in the process of heart failure, can improve the patient’s cardiac function, with good medical results.